secwatch.observer — SEC 8-K summary
======================================

Issuer:     Azitra, Inc. (AZTR)
CIK:        0001701478
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001493152-24-018497
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Azitra Q1 2024 net loss $2.9M; cash $3.0M; ATR-12/ATR-04 clinical updates
-------------------------------------------------------------------------

- Q1 2024 net loss $2.9M vs $2.5M YoY; R&D and G&A each $1.5M vs $0.8M prior year.
- Cash and cash equivalents $3.0M as of 3/31/2024; raised $5.0M in Feb 2024 follow-on offering.
- ATR-12 Phase 1b trial activated sites, initial patients identified; safety data expected late 2024.
- ATR-04 pre-IND meeting completed; IND submission planned mid-2024 for Phase 1b in EGFRi rash.
- Bayer joint development agreement progresses; licensing agreement with upfront payment under discussion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701478/000149315224018497/0001493152-24-018497-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701478/000149315224018497/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-018497

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer